Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

American Journal of Psychiatry

Volumn 156, Issue 10, 1999, Pages 1646-1649

  Adler, Caleb M ^a,b   Malhotra, Anil K ^a   Elman, Igor ^a   Goldberg, Terry ^a   Egan, Michael ^a   Pickar, David ^a   Breier, Alan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; LANGUAGE; MALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; THINKING; THOUGHT DISORDER;

EID: 0032859516     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.10.1646     Document Type: Article

References (28)

1. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989; 77:231-236
2. Kerwin R, Patel S, Meldrum BS, Czudek C, Reynolds GP: Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1988; 12:25-32
3. Kim JS, Kornhuber HH, Holzmuller B, Schmid-Burgk W, Mergner T, Krzepinski G: Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients. Arch Psychiatr Nervenkr 1980; 228:7-10
4. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R: Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiatry 1959; 81:363-369
5. Lahti AC, Koffel B, LaPorte D, Tamminga CA: Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 1:9-19
6. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A: Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17:141-150
7. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A: NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14:301-307
8. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS: Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214
9. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
10. Adler CM, Goldberg TM, Malhotra AK, Pickar D, Breier A: Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry 1998; 43:811-816
11. Andreasen NC: Scale for the Assessment of Thought, Language, and Communication (TLC). Schizophr Bull 1986; 12: 473-482
12. Mazumdar PK, Chaturvedi SK, Sinha V, Gopinath PS: Scale for Assessment of Thought, Language and Communication in psychotic in-patients. Psychopathology 1991; 24:199-202
13. Harvey PD, Earle-Boyer EA, Wielgus MS: The consistency of thought disorder in mania and schizophrenia: an assessment of acute psychotics. J Nerv Ment Dis 1984; 172:458-463
14. Harvey PD, Lombardi J, Leibman M, Parrella M, White L, Powchik P, Mohs RC, Davidson M, Devis KL: Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Am J Psychiatry 1997; 154:205-210
15. Mazumdar PK, Chaturvedi SK, Gopinath PS: A comparative study of thought disorder in acute and chronic schizophrenia. Psychopathology 1995; 28:185-189
16. Cuesta MJ, Peralta V: Does formal thought disorder differ among patients with schizophrenic, schizophreniform and manic schizoaffective disorders? Schizophr Res 1993; 10: 151-158
17. Ragin AB, Oltmanns TF: Communicability and thought disorder in schizophrenics and other diagnostic groups: a follow-up study. Br J Psychiatry 1987; 150:494-500
18. Harvey PD, Lenzenweger MF, Keefe RS, Pogge DL, Serper MR, Mohs RC: Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder. Psychiatry Res 1992; 44:141-151
19. Spitzer RL, Williams JBW, Gibbon M, First HB: Structured Clinical Interview for DSM-III-R - Patient Version 1.0 (SCID-P). Washington, DC, American Psychiatric Press, 1990
20. Cohen S: LSD: the varieties of psychotic experience. J Psychoactive Drugs 1985; 17:291-296
21. Tomiyama G: Chronic schizophrenia-like states in methamphetamine psychosis. Jpn J Psychiatr Neurol 1990; 44:531-539
22. Harvey PD, Davidson M, White L, Keefe RSE, Hirschowitz J, Mohs RC, Davis KL: Empirical evaluations of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the Brief Psychiatric Rating Scale. Biol Psychiatry 1996; 40:755-760
23. Cohen ML, Chan SL, Bhargava HN, Trevor AJ: Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol 1974; 23:1647-1652
24. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci 1980; 26:789-795
25. Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS: Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology 1981; 20:391-396
26. Oye I, Hustveit O, Moberg ER, Pausen O, Skoglund LA: The chiral forms of ketamine as probes for NMDA receptor function in humans, in NMDA Receptor Related Agents: Biochemistry, Pharmacology, and Behavior. Edited by Kameyama T, Nabeshima T, Domino EF. Ann Arbor, Mich, NPP Books, 1991, pp 381-389
27. Byrd LD, Standish LJ, Howell LL: Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol 1987; 144:331-341
28. Rothman S: Noncompetitive N-methyl-D-aspartate antagonists affect multiple ionic currents. J Pharmacol Exp Ther 1988; 246:137-142